Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models
Fig 5
Hippocampal injection of K18PL PFFs leads to robust tau pathology in young PS19 mice.
K18PL PFFs were injected into the hippocampus and mice evaluated 4 weeks later. A. Robust hippocampal AT8 staining on the ipsilateral (Ipsi) side of the PFF injection and on the opposite contralateral (Contra) side at a superior horizontal plane. Right panels show enlarged views of ipsilateral and contralateral hippocampi. Scale bar is 500 μm. B. Distinct AT8 staining in the hippocampus (H) and in the entorhinal cortex (EC) in regions inferior to the site of PFF injections. Right panels show enlarged views of the ipsilateral and contralateral hippocampi and EC. Scale bar is 500 μm. C. Area occupied by AT8 p-tau immunostaining in the ipsilateral and contralateral sides of the hippocampus and EC. D. Cell body counts positive for AT8 p-tau in the ipsilateral and contralateral sides of the hippocampus and EC. Statistical analyses in C. and D, compared all groups to ipsilateral hippocampus, the site of PFF injection, by ANOVA followed by Dunnett’s test (* p<0.05, ** p<0.01). E. Effect of genotype and PFF injections on novel object recognition performance. The total time spent on novel (filled bar) and familiar objects (open bar) are plotted for each treatment group. The different groups included WT, naive (un-injected), and PBS- or K18PL PFF-injected PS19 mice. Statistical comparisons between the time spent on novel and familiar objects for each animal in a group was performed using a pairwise T-test. (** p<0.01; n = 8-14/group).